MX2020004221A - Composicion farmaceutica que comprende derivado de quinolina. - Google Patents

Composicion farmaceutica que comprende derivado de quinolina.

Info

Publication number
MX2020004221A
MX2020004221A MX2020004221A MX2020004221A MX2020004221A MX 2020004221 A MX2020004221 A MX 2020004221A MX 2020004221 A MX2020004221 A MX 2020004221A MX 2020004221 A MX2020004221 A MX 2020004221A MX 2020004221 A MX2020004221 A MX 2020004221A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
composition containing
quinoline derivative
containing quinoline
derivative
Prior art date
Application number
MX2020004221A
Other languages
English (en)
Inventor
Xinhua Zhang
Daimei Zhang
Chenyang Wang
Jianfeng Bai
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2020004221A publication Critical patent/MX2020004221A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente invencion tambien provee una composicion farmacéutica que comprenden un derivado de quinolina; especificamente, la presente invencion proporciona un proceso para preparar una composicion farmacéutica que comprende (R,E)-N-(4-(3-cloro-4-(piri din-2-ilmetoxi) fenilamino)- 3-ciano-7-etoxiquinolin-6-yl)-3-(1-me tilpirrolidinil-2-il)-acrilamida o una sal farmacológicamente aceptable de la misma; el proceso de preparacion es adecuado para una produccion industrial a gran escala, y la muestra obtenida tiene las características tales como una disolución rápida y uniforme.
MX2020004221A 2017-10-24 2018-10-23 Composicion farmaceutica que comprende derivado de quinolina. MX2020004221A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711002771 2017-10-24
PCT/CN2018/111388 WO2019080830A1 (zh) 2017-10-24 2018-10-23 一种含有喹啉衍生物的药物组合物

Publications (1)

Publication Number Publication Date
MX2020004221A true MX2020004221A (es) 2020-07-22

Family

ID=66246218

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004221A MX2020004221A (es) 2017-10-24 2018-10-23 Composicion farmaceutica que comprende derivado de quinolina.

Country Status (13)

Country Link
US (1) US11701349B2 (es)
EP (1) EP3701948A4 (es)
JP (1) JP2021500363A (es)
KR (1) KR20200078561A (es)
CN (1) CN110769825B (es)
AU (1) AU2018357438A1 (es)
BR (1) BR112020007873A2 (es)
CA (1) CA3079916A1 (es)
MX (1) MX2020004221A (es)
RU (1) RU2020115172A (es)
TW (1) TWI700086B (es)
UA (1) UA125706C2 (es)
WO (1) WO2019080830A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202115027A (zh) * 2019-08-30 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 低雜質含量的酪胺酸激酶抑制劑
CN113521074A (zh) * 2020-04-17 2021-10-22 南京圣和药业股份有限公司 一种包含喹啉类TGF-β1抑制剂的组合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102020639A (zh) 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
SI2498756T2 (sl) * 2009-11-09 2023-04-28 Wyeth Llc Tabletne formulacije neratinib maleata
CN102675287A (zh) 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
CN103539783A (zh) 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
CN106913529B (zh) * 2015-12-24 2020-12-04 江苏恒瑞医药股份有限公司 一种来那替尼或其可药用盐药物组合物的制备方法
JP6937308B2 (ja) * 2016-01-27 2021-09-22 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． キノリン誘導体またはその塩を含有する医薬組成物の製造方法
MX2018008549A (es) 2016-01-27 2018-09-19 Jiangsu Hengrui Medicine Co Composicion farmaceutica que comprende derivado de quinolina o sal del mismo.

Also Published As

Publication number Publication date
RU2020115172A (ru) 2021-11-01
AU2018357438A1 (en) 2020-05-07
CN110769825A (zh) 2020-02-07
EP3701948A4 (en) 2021-08-25
WO2019080830A1 (zh) 2019-05-02
KR20200078561A (ko) 2020-07-01
CN110769825B (zh) 2022-06-21
RU2020115172A3 (es) 2021-11-16
JP2021500363A (ja) 2021-01-07
UA125706C2 (uk) 2022-05-18
TWI700086B (zh) 2020-08-01
BR112020007873A2 (pt) 2020-11-03
US11701349B2 (en) 2023-07-18
TW201916881A (zh) 2019-05-01
US20210186952A1 (en) 2021-06-24
EP3701948A1 (en) 2020-09-02
CA3079916A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
MX2020004084A (es) Agentes farmaceuticos como inhibidores del rsv para utilizar en combinacion.
GEP20217239B (en) Pharmaceutical composition
IL254714A0 (en) History of quinoline and pharmaceutical preparations containing them
MX2020003421A (es) Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
MX2020003760A (es) Formulaciones de niraparib.
IL271986A (en) pharmaceutical preparation
MX2020004071A (es) Derivados de aztreonam y usos de los mismos.
GEP20217240B (en) Pharmaceutical composition
MX2020004424A (es) Formulacion aerosolizable.
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
GB201712159D0 (en) Pharmaceutical composition
PH12017502028A1 (en) Vortioxetine pyroglutamate
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
EP3581183A4 (en) PHARMACEUTICAL COMPOSITION FOR ONCOTHERAPY
EP3583943A4 (en) PHARMACEUTICAL COMPOSITION
GB201719447D0 (en) Pharmaceutical composition
IL272419A (en) Pharmaceutical composition
MX2020003616A (es) Nuevo derivado de fenilpiridina y composicion farmaceutica que lo contiene.
EP3720844A4 (en) MEDICINAL COMPOSITIONS
MX2020004221A (es) Composicion farmaceutica que comprende derivado de quinolina.
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
IN2014MU00626A (es)
EP3727485C0 (en) PHARMACEUTICAL COMPOSITION
EP3154524A4 (en) Extended-release drug delivery compositions